Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

iPS Cell Differentiation01:22

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
Acne Infection01:27

Acne Infection

Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Linoleic acid concentration at the air-liquid interface is key for optimal incorporation into skin model lipidome.

Frontiers in physiology·2026
Same author

Alteration of epidermal lipid metabolism by 2-linoleoylglycerol in a 3D skin model.

Scientific reports·2026
Same author

A tissue-engineered human psoriatic skin model: targeting inflammation and glucose metabolism dysregulation in psoriasis using microneedle patches.

Frontiers in molecular biosciences·2026
Same author

Microneedle Technology in Psoriasis Management: Mechanistic Insights, Technological Innovation, Clinical Progress, and Challenges.

Advanced healthcare materials·2025
Same author

Toward Long-Acting Psoriasis Therapy with Phloretin-Loaded Microneedle Patches: Insights from <i>In Vitro</i> Patient-Derived Skin Models.

ACS pharmacology & translational science·2025
Same author

Dissolving microneedles in transdermal drug delivery: A critical analysis of limitations and translation challenges.

Journal of controlled release : official journal of the Controlled Release Society·2025

Related Experiment Video

Updated: May 8, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Promising new treatments for psoriasis.

Sarah Dubois Declercq1, Roxane Pouliot

  • 1Centre LOEX de l'Université Laval, Génie Tissulaire et Régénération, LOEX-Centre de Recherche FRSQ du CHU, Aile-R, 1401 18e Rue, Québec, QC G1J 1Z4, Canada.

Thescientificworldjournal
|August 13, 2013
PubMed
Summary

New biological drugs offer a promising, less toxic alternative for treating moderate-to-severe plaque psoriasis by targeting specific immune pathways. These advanced therapies aim to improve patient quality of life beyond traditional symptom relief.

Related Experiment Videos

Last Updated: May 8, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Psoriasis is a chronic inflammatory skin condition affecting 2-3% of the population, characterized by red, scaly plaques.
  • Current treatments like methotrexate and ciclosporin manage symptoms but do not offer a cure.
  • Understanding psoriasis's immunological basis has led to the development of targeted biological therapies.

Purpose of the Study:

  • To review current and emerging biological treatments for moderate-to-severe plaque psoriasis.
  • To detail the characteristics and mechanisms of action of these novel therapies.
  • To assess their potential as alternatives to conventional treatments.

Main Methods:

  • Review of existing literature on psoriasis treatments.
  • Analysis of clinical trial data for biological drugs.
  • Examination of immunological pathways involved in psoriasis pathogenesis.

Main Results:

  • Biological drugs demonstrate high efficacy and tolerability in treating moderate-to-severe plaque psoriasis.
  • They offer a targeted approach, potentially reducing toxicity compared to traditional systemic therapies.
  • These treatments represent a significant advancement in managing psoriasis.

Conclusions:

  • Biological therapies are a well-tolerated and effective alternative for moderate-to-severe plaque psoriasis.
  • Further research is needed to fully understand their long-term effectiveness and side effect profiles.
  • These advancements hold promise for improving the quality of life for psoriasis patients.